Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Tolerability and efficacy of magrolimab plus azacitidine in TP53-mutated AML patients

Naval Daver • 11 Jun 2022
EHA 2022
Acute Myeloid Leukemia Leukemia Azacitidine Magrolimab

Naval Daver, MD, University of Texas MD Anderson Cancer Center, Houston, TX, shares some insights into the tolerability and efficacy of magrolimab plus azacitidine in TP53-mutated acute myeloid leukemia (AML) patients, highlighting the promising response rates and overall survival, as well as the future role of this combination in the treatment of these patients. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Naval Daver

New treatments in AML: FLT3 inhibitors & novel combinations
Gail Roboz et al. • 4 Sep 2023
3:53
Investigating the combination of pivekimab sunirine, azacitidine & venetoclax in R/R AML
Naval Daver • 12 Dec 2022
1:13
The importance of CD47 as a target in MDS and AML
Naval Daver • 12 Dec 2022
3:50
Investigating the safety & efficacy of magrolimab, azacitidine & venetoclax in patients with AML
Naval Daver • 12 Dec 2022

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals